Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
This study has been completed.
Study NCT00032747   Information provided by Sanofi

First Received on March 29, 2002.   Last Updated on June 16, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Heart Failure
Additional conditions recognized in this trial
Heart Failure
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Interventions listed in this trial
Vasopressin V2 Receptor Antagonist
Additional drug interventions recognized in this trial
Arginine Vasopressin
Vasopressins
More general drug interventions related to this trial
Antidiuretic Agents
Cardiovascular Agents
Coagulants
Hematologic Agents
Hemostatics
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasoconstrictor Agents
Sponsors listed in this trial
Sanofi


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services